Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Episode 16: PLACE Trial: Half-Dose PDT vs Micropulse Laser for Central Serous Chorioretinopathy with Dr. Camiel Boon
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-Release Axitinib Implant (OTX-TKI) for NPDR
Dilsher S. Dhoot, MD
Annual Meeting Talks
2024

Category: Diabetic Retinopathy

See more